Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions (PiCASO)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03938324 |
Recruitment Status :
Recruiting
First Posted : May 6, 2019
Last Update Posted : July 5, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Sickle Cell Disease Chronic Kidney Diseases Systemic Lupus Erythematosus Childhood Cancer Inflammatory Bowel Diseases Stem Cell Transplant Organ Transplant Diabetes Mellitus, Type 1 Cystic Fibrosis | Behavioral: PiCASO Intervention Group Behavioral: Sham Comparator: Attention Control Group | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 225 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Five year randomized controlled trial to test efficacy of behavioral intervention versus attention control group on primary and secondary outcomes across 12 months. |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | Peer i-Coaching for Activated Self-management Optimization in Adolescents and Young Adults With Chronic Conditions |
Actual Study Start Date : | October 29, 2019 |
Estimated Primary Completion Date : | February 29, 2024 |
Estimated Study Completion Date : | February 29, 2024 |

Arm | Intervention/treatment |
---|---|
Experimental: PiCASO Intervention Group
Peer coaching intervention delivered by young adults with a childhood onset chronic condition and trained in coaching curriculum that includes motivational interviewing techniques and the benefits of peer relationships over a shared experience such as a chronic condition. The peer coach supports the AYA to identify their goals and feel a sense of success in making change towards goals within a supportive environment. This process involves goal-setting, development of self-discovery and accountability for changes in health behavior. The peer coach elicits the AYA's vision of optimal health and identifies the AYAs values. As the AYAs identify a vision of wellness and develop goals and action steps to progress towards that vision, the peer coach elicits the AYA's intrinsic motivation and activates skill development in self-advocacy and communication and empowers the AYA to take leadership in managing their condition.
|
Behavioral: PiCASO Intervention Group
This mobile health intervention utilizes an established telephone/text based secure interface to allow AYAs access knowledge, experience, and instrumental/emotional support from a trained peer coach who has already developed independence an active self-manager. Peers with shared experiences provide instrumental (e.g., health maintenance skills) and emotional support that likely lead to improvements in quality of life. Involving peers in supporting AYAs with chronic conditions to promote self-management and patient activation disrupts the typical over-reliance on the parent and health care provider that often impedes developing independence. |
Sham Comparator: Attention Control Group
Over 12 months the attention control group participants will receive a monthly electronic newsletter with educational content about childhood onset chronic condition management and the differences between pediatric and adult health care systems, as well as a monthly phone call from study staff to ensure receipt of the newsletter and to answer questions regarding content, and an opportunity to link them to other resources. If participants report health concerns they will be directed to contact their health care team.
|
Behavioral: Sham Comparator: Attention Control Group
Over 12 months the attention control group participants will receive a monthly electronic newsletter with educational content about childhood onset chronic condition management and the differences between pediatric and adult health care systems, as well as a monthly phone call from study staff to ensure receipt of the newsletter and to answer questions regarding content, and an opportunity to link them to other resources. If participants report health concerns they will be directed to contact their health care team. |
- Change in Self-management as measured by the Partners in Health Scale [ Time Frame: baseline 3-, 6-, 9-, 12 months ]Self-management variable measured using the Partners in Health Scale (PIH): measures chronic illness self-management by assessing chronic condition self-management knowledge, partnership in treatment, recognition and management of symptoms, and coping. This 12 item self-report scale is scored on a 9-point Likert scale (range: 0-8; higher scores indicate better self-management), providing total and subscale scores (knowledge, coping, recognition and management of functions, adherence to treatment).
- Change in Patient activation as measured by the Patient Activation Measure (PAM-13) [ Time Frame: baseline 3-, 6-, 9-, 12 months ]Patient Activation variable measured using the Patient Activation Measure (PAM-13): measures patient activation through self-reports of knowledge, skills, and confidence related to self-management of one's own health care. This 13-item self-report assesses confidence in self-management and understanding of health condition and is scored on a 5-point Likert scale (range: 0-100 with higher scores indicating higher patient activation in self-management).
- Change in Transition Readiness as measured by the Transition Readiness Questionnaire (TRAQ 20) [ Time Frame: baseline 3-, 6-, 9-, 12 months ]Transition readiness variable measured using Transition Readiness Assessment Questionnaire (TRAQ 20): 20-item self-report assessment of the ability to make appointments, manage medications, track health issues, talk with providers, and manage daily activities. The TRAQ scores produced include an overall score and a subscale score for each of the five subscales. The overall score and the subscale scores are calculated by taking the average score across the items in the questionnaire (or subscale). Each item is scored 1-5. Higher scores indicate more transition readiness
- Change in Health-related Quality of Life as measured by the Short Form Health Survey (SF12) [ Time Frame: baseline 3-, 6-, 9-, 12 months ]Health-related Quality of Life variable measured using the Short Form Health Survey (SF12): 12-item self-report that assesses physical and mental health related quality of life. Results are expressed in terms of two meta-scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). The PCS and MCS scores have a range of 0 to 100 and were designed to have a mean score of 50. Higher scores indicate better physical functioning.
- Change in Emotional Health as measured by the Brief Symptom Inventory (BSI 18) [ Time Frame: baseline 3-, 6-, 9-, 12 months ]Emotional health variable measured using the Brief Symptom Inventory: 18-item self-report of emotional symptoms experienced over the previous 7 days. Subscales include depression, anxiety, and somatization. 5-point Likert scale, with three sub-scale scores and an overall global psychological distress score. Higher scores indicate more psychological distress.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 16 Years to 22 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Gender Based Eligibility: | Yes |
Gender Eligibility Description: | Self-representation of gender identity |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- AYA 16 to 22 years
- Childhood onset chronic condition from 1 of 3 condition categories
- Read and speaks English
- Access to internet via computer or Smart Phone
- Access to telephone (Smart Phone not required as text feature can be accessed via internet)
Exclusion Criteria:
- Diagnosed cognitive dysfunction
- Need for English translator

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03938324
Contact: Sharron L Docherty, PhD | 919-668-3836 | sharron.docherty@duke.edu | |
Contact: Gary Maslow, MD | 919-797-5363 | gary.maslow@duke.edu |
United States, North Carolina | |
Duke University | Recruiting |
Durham, North Carolina, United States, 27710 | |
Contact: Angel Barnes, BSN 919-684-4179 angel.barnes@duke.edu | |
Contact: Sharron L Docherty, PhD 9196683836 sharron.docherty@duke.edu |
Study Director: | Angel Barnes, BSN | Duke University School of Nursing |
Responsible Party: | Duke University |
ClinicalTrials.gov Identifier: | NCT03938324 |
Other Study ID Numbers: |
Pro00102191 1R01NR018379-01 ( U.S. NIH Grant/Contract ) |
First Posted: | May 6, 2019 Key Record Dates |
Last Update Posted: | July 5, 2022 |
Last Verified: | June 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Cystic Fibrosis Inflammatory Bowel Diseases Kidney Diseases Renal Insufficiency, Chronic Anemia, Sickle Cell Lupus Erythematosus, Systemic Diabetes Mellitus, Type 1 Chronic Disease Pathologic Processes Urologic Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Male Urogenital Diseases Renal Insufficiency |
Disease Attributes Pancreatic Diseases Digestive System Diseases Lung Diseases Respiratory Tract Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases Intestinal Diseases Gastrointestinal Diseases Gastroenteritis Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia Hematologic Diseases Hemoglobinopathies |